Ribonucleic Acid (RNA) Sequencing Market Report 2026

The ribonucleic acid (rna) sequencing market size has grown exponentially in recent years. It will grow from $3.96 billion in 2025 to $4.84 billion in 2026 at a compound annual growth rate (CAGR) of 22.3%. The growth in the historic period can be attributed to growth of genomics research initiatives, declining sequencing costs, expansion of academic research funding, increased use of next-generation sequencing, rising demand for gene expression analysis.

The ribonucleic acid (rna) sequencing market size is expected to see rapid growth in the next few years. It will grow to $9.63 billion in 2030 at a compound annual growth rate (CAGR) of 18.8%. The growth in the forecast period can be attributed to increasing adoption of precision medicine approaches, rising investments in transcriptomics research, expansion of clinical diagnostic sequencing, growing integration of ai-driven data analysis, increasing focus on personalized therapeutics. Major trends in the forecast period include increasing adoption of single-cell rna sequencing, rising use of high-throughput sequencing platforms, growing integration of advanced bioinformatics tools, expansion of clinical and translational research applications, enhanced focus on data accuracy and reproducibility.

The growing emphasis on precision medicine is anticipated to drive the expansion of the ribonucleic acid (RNA) sequencing market in the coming years. Precision medicine, also known as personalized medicine, is an advanced approach to healthcare that tailors treatment and prevention strategies based on individual differences in genetics, environment, and lifestyle. The increasing adoption of personalized medicine is supported by rapid advancements in genomics, rising disease complexity, and favorable regulatory initiatives, all of which are encouraging the development of more effective and targeted therapies. RNA sequencing technologies play a critical role in precision medicine by determining RNA sequences and quantifying gene expression levels within biological samples. These technologies enable comprehensive transcriptome analysis, offering insights into gene expression patterns, alternative splicing events, and RNA modifications. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the US Food and Drug Administration approved 16 novel personalized therapies for rare disease patients in 2023, compared to six approvals in 2022. Therefore, the increasing focus on precision medicine is fueling the growth of the RNA sequencing market.

Major companies operating in the ribonucleic acid (RNA) sequencing market are concentrating on the development of advanced RNA next-generation sequencing assays to enhance patient care through data-driven insights and precision diagnostics. RNA next-generation sequencing assays utilize advanced genomic sequencing technologies to analyze RNA transcripts at high resolution, supporting detailed molecular profiling. For instance, in June 2023, Tempus, a US-based precision medicine technology company, launched its standalone RNA next-generation sequencing assay, Tempus xR. Designed for solid tumor analysis, the Tempus xR assay provides comprehensive whole-transcriptome profiling, identifying clinically relevant gene fusions across more than 100 targeted genes, as well as detecting altered splicing events such as MET Exon 14 and EGFRvIII. This solution addresses the needs of clinicians, researchers, and biopharmaceutical companies seeking in-depth RNA sequencing insights from existing samples.

In January 2024, Parse Biosciences, a US-based biotechnology company specializing in innovative research and diagnostic solutions, acquired Biomage for an undisclosed amount. Through this acquisition, Parse Biosciences aims to integrate Biomage’s advanced data analysis capabilities, including its Cellenics cloud-based platform, with Parse’s Evercode combinatorial barcoding technology to strengthen its RNA sequencing and data analytics offerings. Biomage Ltd. is a UK-based company that provides RNA sequencing analysis software and related services.

Major companies operating in the ribonucleic acid (rna) sequencing market are F Hoffmann La Roche Ltd, Thermo Fisher Scientific Inc, Danaher Corporation, Merck KGaA, Becton Dickinson And Company, Eurofins Scientific SE, Agilent Technologies Inc, Illumina Inc, PerkinElmer Inc, Beckman Coulter Inc, Bio Rad Laboratories Inc, QIAGEN NV, Tecan Genomics Inc, BGI Genomics Co Ltd, Takara Bio Inc, Abcam Limited, Oxford Nanopore Technologies plc, Pacific Biosciences Of California Inc, Macrogen Inc, Standard BioTools Inc, CD Genomics, Genewiz Inc, Novogene Co Ltd, GENEWIZ Germany GmbH, Azenta Life Sciences.

North America was the largest region in the ribonucleic acid (RNA) sequencing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ribonucleic acid (rna) sequencing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ribonucleic acid (rna) sequencing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the RNA sequencing market by increasing costs of imported sequencing instruments, reagents, consumables, and bioinformatics software components. Research institutions and pharmaceutical companies in North America and Europe are most affected due to reliance on global suppliers, while Asia-Pacific faces higher costs for imported high-end sequencing platforms. These tariffs increase research expenses and extend procurement cycles. However, they also encourage local reagent manufacturing, regional instrument assembly, and development of domestic bioinformatics capabilities.

The ribonucleic acid (rna) sequencing market research report is one of a series of new reports that provides ribonucleic acid (rna) sequencing market statistics, including ribonucleic acid (rna) sequencing industry global market size, regional shares, competitors with a ribonucleic acid (rna) sequencing market share, detailed ribonucleic acid (rna) sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the ribonucleic acid (rna) sequencing industry. This ribonucleic acid (rna) sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ribonucleic acid (RNA) sequencing is a technique that employs next-generation sequencing technologies to determine the presence and abundance of RNA molecules in a biological sample, offering a detailed snapshot of gene expression. It allows researchers to analyze gene expression patterns, discover novel transcripts, and gain insights into RNA processing.

The main product types of ribonucleic acid (RNA) sequencing include instruments, reagents and kits, and software. Instruments used in RNA sequencing are the physical equipment and tools required to process and analyze RNA molecules, such as sequencers and polymerase chain reaction machines, and are essential for accurate sample analysis. The technologies involved include single-molecule-based sequencing, sequencing by synthesis technology, nanopore sequencing technology, and ion torrent semiconductor sequencing. These technologies are applied across various areas such as diagnostics, drug discovery, translational medicine, and others, and are utilized by end users including research and academic institutions, hospitals and clinics, pharmaceutical and biotechnology companies, and others.

The ribonucleic acid (RNA) sequencing market consists of revenues earned by entities by providing services such as library preparation, RNA extraction, fragmentation, reverse transcription, adapter ligation, sequencing, data analysis, bioinformatics support, consultation and experimental design, quality control, sample preparation services, gene cloning, genotyping and mutation detection, and pathogen detection. The market value includes the value of related goods sold by the service provider or included within the service offering. The ribonucleic acid (RNA) sequencing market also includes sales of library preparation kits, RNA extraction kits, quantification kits, polymerase chain reaction (PCR) instruments, pipette tips, tubes, and plates. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.